Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Plug Power

Super Micro Computer

Short squeezes affect heavily shorted stocks when many sellers are forced to buy back the shares they shorted. That dynamic, in turn, causes the stock's price to soar, creating more purchases by short sellers and causing the process to continue.

3 Top Short Squeeze Stocks for August 2023

Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.10 per share a year ago.

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO Chris Stewart - CFO Conference Call Participants Jason McCarthy - Maxim Group Mark Massaro - BTIG Sung Ji Nam - Scotiabank Daniel Hultberg - Oppenheimer Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano's Second Quarter 2023 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q2 2023 Earnings Call Transcript

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2023.

Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress

Bionano Genomics (NASDAQ: BNGO ) effected a 1-for-10 reverse stock split and announced that it will publish quarterly earnings on Aug. 9. Shares opened this morning at $4.73 each, a market capitalization of $1.49 billion.

BNGO Stock Alert: Bionano Just Reverse Split Its Stock

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. The Company's common stock will begin trading on a split-adjusted basis commencing upon market open on August 7, 2023.

Bionano Genomics Announces Reverse Stock Split

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.

Bionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023

ImmunityBio

Novavax

American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable in America in particular.

Looking for a Bargain? 3 Biotech Stocks to Buy That Are Down 20%-60% in 2023

Brenmiller Energy Ltd

Faraday Future Intelligent Electric

Senseonics Holdings

Soluna Holdings, Inc.

T2 Biosystems

Today's penny stock market is brimming with high-volatility stocks. That especially relates to those that fall into the category of the cheapest penny stocks.

Best Penny Stocks To Buy Now? 6 Under $1 To Watch Now

Some of the most volatile penny stocks today are the cheapest. This idea of “cheap” is in the sense that prices are extremely low compared to other stocks.

3 Penny Stocks Under $1 To Watch Before August 2023

Axcelis Technologies

e.l.f. Beauty

General Electric

ServiceNow

Rivian Automotive

Workday

This is a great time for investors to buy the best growth stocks. In addition to America's very strong macro trends, many companies have been reporting excellent results in the last several weeks.

The 7 Best Growth Stocks to Buy in July

SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the Stratys™ system for high throughput optical genome mapping (OGM) and VIA™ software for visualization, interpretation and reporting of genome analysis for OGM, microarrays and next-generation sequencing (NGS) data in one integrated software platform. VIA further incorporates these data into an intuitive and powerful workflow for hematologic malignancies.

Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies

Aeglea BioTherapeutics

Amyris

 Clene Nanomedicine

Clearmind Medicine Inc

Cybin

Hyzon Motors

IronNet

NeuroBo Pharmaceuticals Inc

Qurate Retail Inc

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

10 Top Penny Stocks To Watch Right Now For Under $1

Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.

7 Penny Stocks To Watch Right Now For Under $1

Harpoon Therapeutics Inc

Nauticus Robotics Inc

With investors looking for growth wherever they can find it, it's a good time to look at penny stocks to watch in 2023. Granted, penny stocks carry a higher risk than blue-chip stocks, but they also carry the potential for outsized returns.

3 Penny Stocks with Multibagger Potential for the Second Half of 2023

Bristol-Myers

GlaxoSmithKline

Inmode Ltd

Inspire Medical Systems Inc

Revance Therapeutics

Viking Therapeutics

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.

7 Healthcare Stocks to Make You the Millionaire Next Door

SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano's president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.

Bionano to Present at the Healthcare Virtual Conference

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting.

Bionano Announces Results from its Annual Meeting of Stockholders

SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr. Michael Khodadoust at Stanford University. Runner up prize winners are The Hospital for Sick Children, whose project will be led by Dr. Afia Hasnain and Duke University, whose project will be led by Dr. Stefan Rentas. All three winners will receive use of a Saphyr system for a period of time and optical genome mapping (OGM) reagents to conduct their project. Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.

Bionano Announces 2023 Winners of its Innovator Research Grant Program

23andMe

Precigen

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich

Shoals Technologies Group

Upstart Holdings

Everyone who invests in growth stocks hopes that one of their holdings will become the next Netflix (NASDAQ: NFLX ), the next Amazon (NASDAQ: AMZN ), or the next Facebook. In other words, they're looking for names that can transform, or disrupt, entire sectors.

3 Growth Stocks That Are Disrupting Their Industries in 2023

Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics First Quarter 2023 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2023.

Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress

Illumina

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

News for Bionano Genomics Stock (BNGO)